2022 spells change for EU pharmaceutical legislation
European Pharmaceutical Review
JUNE 24, 2022
Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product. He focuses his practice on EU regulatory affairs, litigation and competition law issues affecting the life sciences sector in Europe. Key areas of potential legislative change.
97 
Let's personalize your content